Healthcare / BiotechnologyNasdaqCM
$4.49
-0.23 (-4.87%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-63.6M · quality 41.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
28/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$222M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-15.1%
↓Gross Margin
89.4%
↑Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2008–2025 · 17 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-1371.4%
FCF / Net income
4.76x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $7.1M · net income $-20.6M · FCF $-98.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||||||||
| Revenue | $7.1M | $7.1M | $26.0M | $24.4M | $15.2M | $14.0M | $14.0M | $0.00 | $20.2M | — | — | — | — | — | — | — | — | — | — |
| Net Income | $-20.6M | $-20.6M | $-63.7M | $-65.8M | $-60.5M | $-110.1M | $-3.5M | $-23.3M | $-10.4M | $-21.4M | $-17.0M | $-31440.00 | $-30799.00 | $-28701.00 | $-27365.00 | $-27185.00 | $-22395.00 | $-19996.00 | $-33623.00 |
| EBITDA | $-20.5M | $-20.5M | $-63.3M | $-65.4M | $-60.1M | $-111.1M | $-2.5M | — | — | — | — | — | — | — | — | — | — | — | — |
| EPS | -0.33 | -0.33 | -2.36 | -2.44 | -2.69 | -12.41 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Gross Margin | 89.4% | 89.4% | 88.4% | 88.5% | 91.2% | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | -1601.1% | -1601.1% | -249.5% | -295.4% | -387.5% | -794.4% | -18.2% | — | -55.5% | — | — | — | — | — | — | — | — | — | — |
| Net Margin | -288.3% | -288.3% | -245.1% | -270.0% | -397.7% | -786.4% | -24.8% | — | -51.6% | — | — | — | — | — | — | — | — | — | — |
| Balance Sheet | |||||||||||||||||||
| Debt/Equity | — | — | 0.02 | 0.01 | 0.01 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Current Ratio | 10.26 | 10.26 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | |||||||||||||||||||
| Free Cash Flow | $-98.0M | $-98.0M | $-61.2M | $-63.6M | $-50.1M | $-22.5M | $-12.7M | $-24.1M | $-5.8M | $-18.9M | $-137814.00 | — | — | — | — | — | — | — | — |
| Returns | |||||||||||||||||||
| ROE | -15.1% | -15.1% | -121.4% | -62.5% | -38.2% | -80.7% | 28.0% | 255.9% | -17.7% | -122.7% | 19.7% | 0.0% | 19.9% | 23.1% | 28.6% | 39.9% | 54.6% | 107.5% | -2401.6% |
| Valuation | |||||||||||||||||||
| P/B | 2.04 | 2.04 | 1.68 | 0.45 | 1.78 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | |||||||||||||||||||
| Revenue Growth | -72.5% | -72.5% | 6.7% | 60.1% | — | 0.0% | — | -100.0% | — | — | — | — | — | — | — | — | — | — | — |
| EPS Growth | 86.0% | 86.0% | 3.3% | 9.3% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+165.7%
Start / end P/E
n/dx → n/dx
EPS bridge
-2.36 → -0.33
Residual
+165.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.